{"id":8630,"date":"2020-03-05T17:01:05","date_gmt":"2020-03-05T11:31:05","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=8630"},"modified":"2021-07-24T12:57:48","modified_gmt":"2021-07-24T07:27:48","slug":"recent-pharma-happenings-for-amunix-car-autism","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism","title":{"rendered":"CAR-T in killing tumors; Amunix raises $73M; Autism findings in protein-targeted treatment"},"content":{"rendered":"\n

Killing brain tumors with the help of CAR-T<\/strong><\/h2>\n\n\n\n

CAR-T cell therapy is a technique which involves modifying patients’ T cells to aim proteins associated with cancer that have revolutionized some of the blood cancers treatment. However, the technique has so far shown low potential in solid tumors like aggressive brain cancer- glioblastoma.<\/p>\n\n\n\n

Now, researchers at the City of Hope have created a novel chimeric antigen receptor (CAR)<\/a> based on chlorotoxin (CLTX), a toxin present in scorpion venom. T cells armed with that CAR <\/a>positively killed tumors in mice with glioblastoma xenografts without stimulating any unwanted consequences, the team informed in a study published in Science Translational Medicine.<\/p>\n\n\n\n

The City of Hope has launched a phase 1 clinical study in partnership with the National Cancer Institute to assess the safety of the novel CLTX-CAR T cells- along with estimating the therapy’s response rate\u2014in glioblastoma (GBM) patients.<\/p>\n\n\n\n

Amunix raises USD 73 Million to take T-cell engager into humans<\/strong><\/h2>\n\n\n\n

Amunix Pharmaceuticals has raised USD 73 Million in series A funding. The Omega Funds-led round makes Amunix up to go ahead with its leading T-cell<\/a> engager into the lab after years of licensing its half-life extension technology to lead drug developers for their candidates.<\/p>\n\n\n\n

The giants, including Biogen, Celgene and Merck, turned to Amunix, California-based company, for technology to increase the half-lives of their medicines. The branded XTEN proffers hydrophilic, unstructured, biodegradable protein chains to drugs to lessen dose frequency.<\/p>\n\n\n\n

Since 2019, Amunix began targeting its internal efforts on the tools’ application that covers a prodrug platform, to T-cell engagers and cytokines, which only become involved in the tumour microenvironment. The work has progressed till the point that Amunix has the proof to bolster a sizable series A round.<\/p>\n\n\n\n

Autism findings hint potential protein-targeted treatments<\/strong><\/h2>\n\n\n\n

Autism <\/a>is a diverse disease, which is a severe developmental disorder that degrades the ability to communicate and interact. The disease that causes a wide range of symptoms, from repetitive behaviours to extreme sensitivity to noise.<\/p>\n\n\n\n

Scientists at the Gladstone Institutes paid heed to tau, a protein that is the most closely associated with Alzheimer’s disease<\/a>. The researchers were examining a link between Alzheimer’s <\/a>and epilepsy <\/a>when they made an astonishing discovery that decreasing levels of tau in mouse models of autism prohibited three of the main symptoms of the disease: repetition, difficulty socializing and impaired communication. It also inhibited seizures, which affect about one-third of autism patients, as they published in the journal-Neuron.  <\/p>\n","protected":false},"excerpt":{"rendered":"

Killing brain tumors with the help of CAR-T CAR-T cell therapy is a technique which involves modifying patients’ T cells to aim proteins associated with cancer that have revolutionized some of the blood cancers treatment. However, the technique has so far shown low potential in solid tumors like aggressive brain cancer- glioblastoma. Now, researchers at […]<\/p>\n","protected":false},"author":1,"featured_media":8631,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17701,18097,628,1983,1976,1982,1494,1787,349,639,5789],"industry":[17225],"therapeutic_areas":[17235],"class_list":["post-8630","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alzheimers","tag-amunix-pharmaceuticals","tag-autism","tag-car","tag-car-t-cell-therapy","tag-chimeric-antigen-receptor","tag-epilepsy","tag-glioblastoma","tag-latest-pharma-news","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy"],"acf":[],"yoast_head":"\nCAR-T in killing tumors; Autism findings in protein-targeted treatment<\/title>\n<meta name=\"description\" content=\"T cells armed with that CAR positively killed tumors in mice with glioblastoma xenografts without stimulating any unwanted consequences.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CAR-T in killing tumors; Autism findings in protein-targeted treatment\" \/>\n<meta property=\"og:description\" content=\"T cells armed with that CAR positively killed tumors in mice with glioblastoma xenografts without stimulating any unwanted consequences.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-05T11:31:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/05164305\/slide1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CAR-T in killing tumors; Autism findings in protein-targeted treatment","description":"T cells armed with that CAR positively killed tumors in mice with glioblastoma xenografts without stimulating any unwanted consequences.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism","og_locale":"en_US","og_type":"article","og_title":"CAR-T in killing tumors; Autism findings in protein-targeted treatment","og_description":"T cells armed with that CAR positively killed tumors in mice with glioblastoma xenografts without stimulating any unwanted consequences.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-03-05T11:31:05+00:00","article_modified_time":"2021-07-24T07:27:48+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/05164305\/slide1.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism","name":"CAR-T in killing tumors; Autism findings in protein-targeted treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/05164305\/slide1.jpg","datePublished":"2020-03-05T11:31:05+00:00","dateModified":"2021-07-24T07:27:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"T cells armed with that CAR positively killed tumors in mice with glioblastoma xenografts without stimulating any unwanted consequences.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-amunix-car-autism#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/05164305\/slide1.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/05164305\/slide1.jpg","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/03\/05164305\/slide1-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alzheimer\u0092s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Amunix Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Autism<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR T-cell Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Chimeric Antigen Receptor<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epilepsy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">glioblastoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alzheimer\u0092s<\/span>","<span class=\"advgb-post-tax-term\">Amunix Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Autism<\/span>","<span class=\"advgb-post-tax-term\">CAR<\/span>","<span class=\"advgb-post-tax-term\">CAR T-cell Therapy<\/span>","<span class=\"advgb-post-tax-term\">Chimeric Antigen Receptor<\/span>","<span class=\"advgb-post-tax-term\">Epilepsy<\/span>","<span class=\"advgb-post-tax-term\">glioblastoma<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 5, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 5, 2020 5:01 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8630","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=8630"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/8630\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/8631"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=8630"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=8630"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=8630"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=8630"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=8630"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}